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Protocol
AbstrACt
Introduction Adverse drug events (ADEs) are common in 
older persons and contribute significantly to emergency 
department visits, hospitalisations and mortality. ADEs are 
often due to potentially inappropriate prescriptions (PIP) or 
potentially inappropriate omissions (PIO), and are avoidable 
if inappropriate prescriptions or omissions are identified 
and prevented. Identifying PIP/PIO at the population 
level through the application of PIP/PIO assessment 
tools to health administrative data can provide a unique 
opportunity to assess the economic burden of PIP/PIO on 
the healthcare system beyond medication costs which is 
yet to be done. The objective of this study is to assess the 
economic burden associated with PIP/PIO and to estimate 
the incremental costs associated with distinct PIP/PIO in 
the province of Ontario.
Methods and analysis We will conduct a retrospective 
cohort study using Ontario’s health administrative 
databases. Eligible patients aged 66 years and older 
who were prescribed at least one medication between 1 
April 2003 and 31 March 2014 (approximately 2.4 million 
patients) will be included. Population attributable fraction 
methodology will be used to assess the overall burden 
of PIP in Ontario, while regression analyses will be used 
to estimate the incremental costs of having specific PIP 
criteria and aid in prioritising targets for intervention.
Ethics and dissemination This study was approved 
by the Institutional Review Board at Sunnybrook Health 
Sciences Centre, Toronto, Canada. Dissemination will occur 
via publication, presentation at national and international 




Adverse drug events (ADEs) are common in 
older persons due to physiological vulner-
ability associated with ageing and disease.1 
These contribute significantly to emergency 
department (ED) visits, unplanned hospi-
talisations,2 and in-hospital morbidity and 
mortality.3 Many of these ADEs are due to 
potentially inappropriate prescriptions (PIPs) 
or potentially inappropriate omissions (PIOs) 
(alternatively named potential prescribing 
omissions) and are avoidable if inappropriate 
prescriptions and/or omissions are identi-
fied and prevented. PIP/PIO is also most 
common in older persons and the likelihood 
of PIP increases as patients are prescribed 
more drugs than may be clinically necessary, 
which is defined as polypharmacy.4 
A number of tools have been developed 
to identify PIP/PIO (referred to as PIP from 
now on unless otherwise specified) in clin-
ical settings, including the STOPP/START 
criteria5 (Screening Tool of Older Persons’ 
Prescriptions/Screening Tool to Alert doctors 
to Right Treatment) and the Beers criteria.6–10 
These tools are time consuming and costly 
to apply individually and are underused. 
Applying these tools to assess the appropri-
ateness of prescribing to population-wide 
health administrative data can provide a 
strengths and limitations of this study
 ► This unique study provides an analytical framework 
to estimate the economic impact of potentially in-
appropriate prescribing (PIP) at the population level.
 ► This study benefits from being able to incorporate 
costs of hospitalisation and emergency department 
visits in addition to medication costs in the assess-
ment of PIP-related costs, as well as the ability to 
adjust for potential confounders beyond age and 
sex, providing a less biased estimate of costs asso-
ciated with PIP.
 ► This study has limitations common to studies using 
health administrative data, primarily uncertainty sur-
rounding patient adherence to medication and lack 
of documentation of some potential confounders.
 ► Identifying the overall costs associated with PIP 
would provide further evidence to support PIP as a 
high priority for healthcare decision-makers, while 
characterising the costs of specific PIP scenarios 
would provide these decision-makers with action-
able targets to address PIP.
2 Black CD, et al. BMJ Open 2018;8:e021727. doi:10.1136/bmjopen-2018-021727
Open access 
unique opportunity to assess both the frequency of PIP 
and its associated costs, in terms of medication and health 
services use, at both the individual and population level.
Evidence gaps to be filled
PIP is associated with increased costs and health services 
use according to studies conducted in Ireland and the 
UK,11–13 but its economic impact in Canada is unknown. 
The PIP-STOPP study is a CIHR-funded project with the 
aim of using subsets of the STOPP/START and Beers’ 
criteria applicable to health administrative data housed 
at the Institute for Clinical Evaluative Sciences (ICES) to 
identify PIP and PIO at the population level in Ontario, its 
association with hospitalisations, ED visits and mortality, 
and health system costs.14
Identifying the overall health system costs associated 
with PIP would provide further evidence to support PIP 
as a high priority for decision-makers by quantifying 
its overall health system burden, while characterising 
the costs of specific PIP scenarios would provide these 
decision-makers with actionable targets to address PIP 
through a better understanding of the flow of costs attrib-
utable to different PIP scenarios and the identification of 
higher cost-burden PIPs.
This study protocol details the methods to assess the 
health system costs associated with PIP overall in Ontario, 
as well as to estimate the incremental costs of PIP scenarios 
which vary by their downstream healthcare resource use 
and by frequency. To address these knowledge gaps, the 
objectives of this study are to:
 ► Assess the overall health system costs associated with 
PIP in Ontario.
 ► Estimate the incremental costs associated with distinct 
PIP scenarios occurring in Ontario.
MEthods
Methods regarding the study design, participants, datasets, 
exposure and cohort size for this study have been exten-
sively described previously in the published protocol of its 
parent study14 and are only summarised here. The methods 
common to both objectives, including study design, partici-
pants and data sources, are listed first, followed by the expo-
sure, outcomes, covariates and statistical analyses relevant 
to each objective.
study design
A population-based, retrospective cohort study design will 
be used, identical to that from previous publications from 
a larger retrospective, population-based cohort study on 
the identification of PIP and predicting patient outcomes 
in Ontario.14
Definition of observation periods
The study period will span from 1 April 2002 to 31 March 
2015, which is based on the availability of the necessary data-
bases. The patient accrual period will be from 1 April 2003 
to 31 December 2014, allowing for a 1-year lookback period 
for prior health services utilisation and baseline covariates, 
as well as a 90-day follow-up period after the last possible 
PIP to allow time for identification of associated outcomes, 
figure 1. We have chosen a 90-day observation window 
following instances of PIP in which to identify outcomes 
because we do not assume that the potential influence of 
PIP would extend beyond this period.
Participants
From the data housed at ICES, a large cohort of patients who 
are eligible for the study (approximately 2 million partic-
ipants) has been identified. These patients are Ontario 
residents aged 66 years and older with Ontario Health 
Insurance Plan (OHIP) drug coverage (approximately 97% 
of Ontario seniors) who have been dispensed at least one 
prescription between 1 April 2003 and 31 December 2014.
data sources
The proposed project will use population-level health 
administrative data from Ontario, which is housed at 
ICES.15 16 Accessing data through ICES allows for the linking 
Figure 1 Definition of observation period. PIP, potentially inappropriate prescription.
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of demographic, socioeconomic, hospital and outpatient 
health services, physician billing datasets, and prescription 
dispensation to Ontarians aged 65 years or older, or those 
requiring social assistance.17 Cost data are available for all 
physician claims, hospitalisations, ambulatory care services, 
home care services, long-term and complex continuing 
care, and medical devices in Ontario, while prescription 
medication cost data are available for those 65 years of age 
or older and those requiring social assistance. The following 
datasets will be linked to gather the appropriate and avail-
able exposure, outcome and covariate data necessary for 
analyses: Ontario Drug Benefits Claims Database (ODBD), 
Discharge Abstract Database, Same Day Surgery Database, 
National Ambulatory Care Reporting System, OHIP data-
base, Registered Persons Database (see online supplemen-
tary appendix A for brief description of each). Additionally, 
five ICES-derived cohorts will be used for case ascertainment 
for specific STOPP/START criteria requiring the following 
diagnoses: asthma, diabetes, hypertension, chronic obstruc-
tive pulmonary disease and congestive heart failure.18
objective 1: overall health system costs due to PIP
Exposure
The subset of STOPP/START criteria applicable to health 
administrative databases were identified based on the 
availability of the data necessary for their use and coded 
into a format applicable to ICES-housed health admin-
istrative data using a combination of medication, diag-
nostic (ie, International Classification of Diseases Codes), 
healthcare services utilisation and physician billing codes. 
This process identified 64% of STOPP criteria and 27% 
of START criteria as applicable to health administrative 
data available through ICES. A manuscript describing the 
coding process in detail is in preparation.19
The exposure of interest will be the first occurrence of 
any PIP identified using health administrative databases 
for each patient in the cohort during the study accrual 
period from 1 April 2003 to 31 December 2014. Unex-
posed patients will be those who have not experienced 
any PIP during the study accrual period.
Outcome
The primary outcome will be the combined medication, 
hospitalisation and ED visit costs attributable to PIP paid 
by the Ontario Ministry of Health and Long-Term Care 
over the 3 months following a PIP. These costs, from 
documented clinical events attributable to PIP, will be 
identified via population attributable fraction (PAF) 
methods.20 21 To identify costs, the ICES costing algorithm 
will be used.22 This algorithm allows for the identification 
of costs from any health services covered by the OHIP 
over a defined time period.22 All costs will be inflated 
to 2015 $C using Statistic Canada’s Consumer Price 
Index.23 The PAF estimates for hospitalisations, ED visits 
and medications will be derived via the incidence rate 
ratios (IRRs) obtained from Poisson or negative binomial 
regression models for each outcome, described in further 
detail in the statistical analyses section. Each PAF estimate 
will then be multiplied by the total cost of their respective 
healthcare service over the 90-day observation period for 
the whole population, which will be totalled to obtain the 
total costs attributable to PIP over the study period.
Though we realise not all hospitalisations and ED visits 
will be causally related with PIP, ADEs are frequently 
under-recognised during ED visits and hospitalisa-
tion.24 25 As such, we chose to use reliably documented 
clinical events (hospitalisation and ED visits) and their 
costs, along with medication costs, as most suitable for 
the primary outcome. These costs were selected as they 
are the costs associated with the most reliably docu-
mented clinical events and those most likely to be linked 
to PIP. For medication costs, only those attributable to 
STOPP criteria will be determined and patients with PIP 
who either have a START criterion as their first PIP, or 
multiple first PIPs, will be excluded from this analysis. 
This is to ensure that all drug costs are attributable to the 
prescribing of a medication (ie, STOPP criteria) and not 
to the omission of medication (ie, START criteria), which 
would in fact result in a reduction in costs.
Covariates
Analyses will be adjusted for potential confounders 
which are available through provincial health admin-
istrative databases and either known or perceived to be 
associated with PIP or with our outcomes of interest (ie, 
hospitalisation, ED visits and medication use), including 
age,26 27 sex,27 income quintile,27 28 rurality, aggregated 
diagnosis group score (ie, comorbidity status),27 29 30 
number of unique drug identification numbers (ie, pills 
prescribed concurrently) in year prior to PIP,31–35 number 
of prescribers in year prior to PIP,36 whether the patient 
had a MedsCheck (billable medication review performed 
by a pharmacist, usually in the community) in year prior 
to PIP, number of days spent in hospital in year prior to 
PIP, ED visit in 6 months prior to PIP.26 27 29 37–41
For this objective, the ascertainment of covariate status 
will be done at the PIP date for participants experiencing 
a PIP and at the randomly assigned index date for partic-
ipants who do not experience a PIP, as further described 
below.
Statistical analyses
The direct costs associated with the occurrence of any 
first PIP in Ontario will be estimated by combing medi-
cation-related and non-medication-related costs attribut-
able to PIP via the steps below.
Assignment of time to PIP for unexposed patients
To estimate the health system costs due to PIP, it is neces-
sary to compare the number of days spent in hospital, the 
number of ED visits and the volume of newly prescribed 
medications in participants with and without PIP. To do 
this, we will need to assign an index date to participants 
without PIP so that they have comparable lookback and 
observation windows for covariate and outcome ascertain-
ment, respectively. The index date for participants not 
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experiencing a PIP will be treated as missing at random. 
We will conduct parametric survival analysis on the partic-
ipants within the cohort who have experienced a PIP, with 
their time-to-first PIP from cohort entry as the response 
variable in the model. The models will be stratified by sex 
and median age during cohort participation according 
to the following categories: 66–70, 71–75, 76–80, 81–85, 
86–90, over 90. The models will be fitted to identify the 
appropriate distribution for its random error compo-
nent. Once the best-fitting model has been identified, the 
resulting distribution and appropriate shape and scale 
parameters, depending on the distribution identified, 
will be applied to the participants without a PIP via the 
random number function in SAS42 in order to randomly 
assign them a PIP index date and identify the start of their 
90-day observation window. This random assignment will 
be done three times, with the first randomly assigned 
PIP index used for the primary analyses and most other 
subgroup and sensitivity analyses, while the other two 
will be used to conduct a sensitivity analysis to determine 
whether the random assignment method used impacts 
study results. Participants with an assigned PIP index date 
that falls beyond the end of their follow-up period will be 
excluded from all analyses. For both exposed and unex-
posed participants, we will determine whether they have 
at least 90 days between their PIP index date and the end 
of their follow-up. If this difference is less than 90 days, 
participants will be removed from the analysis.
This approach to assignment of an index date in 
non-PIP participants was selected over simple random 
assignment of time to PIP since the underlying distribu-
tion of time-to-first PIP in participants experiencing PIP 
is unknown and is not believed to be normally distributed 
and is also thought to vary by age and sex. We do not 
consider matching as an option due to the high preva-
lence of PIP in the older population resulting in a diffi-
culty to find suitable matches for all participants with a 
PIP. Additionally, the first day of a participant’s inclu-
sion in the study population for participants without PIP 
cannot be used as their PIP index date as this would make 
the unexposed group systematically younger than those 
exposed to PIP during analyses, resulting in confounding 
that may not be completely adjusted for even though age 
is being included in analyses as a covariate.
Medication use, ED visits and hospitalisations attributable to PIP
The IRRs for ED visits, days spent in hospital and medi-
cations for participants with PIP versus those without PIP 
will be determined via parameter estimates for the PIP 
variable from regression models for count data. Three 
models will be created, each with the response variable 
of either count of ED visits, days spent in hospital and 
total number of unique, newly prescribed medications in 
the 90-day period following their PIP date for participants 
with PIP, or the randomly assigned PIP index date for 
participants not experiencing a PIP. Each of the models 
will be adjusted for the covariates listed previously. For 
each outcome, either a Poisson or negative binomial 
model will be fitted based on a comparison of the mean 
of the response variable with its variance to determine if 
overdispersion is present.43 Should the mean and variance 
be equal, or approximately so, then the Poisson model 
will be used. If the variance is greater and proportional 
to the mean, indicating overdispersion, then the negative 
binomial model will be used. The IRRs obtained via the 
parameter estimate for the PIP variable in the best-fit-
ting model for each outcome will be used to derive their 
respective PAF in combination with the proportion of the 
population exposed to PIP (Pexp), obtained directly from 
our cohort as the PIP prevalence in the whole study popu-
lation, via Levin’s formula: ((Pexp*(RR-1))/((Pexp(RR-
1))+1))*100.20 21
Total costs attributable to PIP
The respective PAFs for ED visits, days spent in hospital 
and medications will be multiplied by the total costs for 
each of these health services, respectively, to obtain the 
total cost of each service use attributable to PIP over 
the 90-day observation period. These costs will then be 
combined to obtain the total health system costs attribut-
able to PIP over the study period. The same methods will 
be used to obtain costs attributable to PIP by year.
Subgroup analyses
Similar methods to those listed above will be conducted in 
order to obtain the costs attributable to PIP by age, cate-
gorised by the median age of cohort participation based 
on the categories described above, and sex. Additionally, 
a subgroup analysis for the ED visit and hospitalisation 
costs will be conducted based on whether a patient’s first 
PIP was a STOPP or START criteria, with patients experi-
encing multiple first PIPs excluded.
objective 2: incremental costs of specific PIP criteria
Exposure
PIP will be identified using the same methods described 
in objective 1. Specific PIP criteria will be selected for the 
assessment of the incremental costs associated with each 
of them. For each of the criteria studied, the exposure of 
interest will be the first time the PIP of interest occurred 
for each participant in the cohort. Exposed participants 
must have never experienced another PIP prior to the 
PIP date, as well as during the 90-day observation window. 
Unexposed participants will not have experienced any 
PIP during their cohort participation.
To identify the PIPs to model, each of the individual 
PIPs applicable to health administrative data was plotted 
on a graph according to their frequency (y-axis) by their 
crude average healthcare services costs (ie, medication, 
hospitalisation and ED visits combined (x-axis), figure 2. 
Two STOPP criteria falling on the high-cost plane were 
identified due to their potential for being high-impact 
PIPs, along with a high-frequency START criterion which 
also fell near this plane. A low-frequency/low-cost STOPP 
criteria was chosen to be used for comparison. The PIPs 
identified were: START A6, STOPP J6, STOPP K2, STOPP 
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D8. START A6 is defined as the omission of ACE inhib-
itor with systolic heart failure and/or documented coro-
nary artery disease. STOPP K2 is defined as the use of 
any neuroleptic drug. STOPP D8 is flagged as a PIP when 
anticholinergics and or antimuscarinics are prescribed 
in participants with delirium or dementia, due to risk of 
exacerbation of cognitive impairment. The final selected 
PIP, STOPP J6, is defined as the prescribing of andro-
gens (male sex hormones) in the absence of primary or 
secondary hypogonadism. The full definitions as they 
appear in the STOPP/START criteria for each of the 
selected criteria are described in table 1, along with their 
categorised frequency and crude costs.5
Outcome
The outcome will be the combined hospitalisation, 
ED visit and PIP medication costs in the 90-day period 
following the PIP date. The ED visit and hospitalisation 
costs will be obtained via the ICES costing algorithm22 
and inflated to 2015 $C. Like the hospitalisation and ED 
visit costs, we will attempt to obtain the PIP medication 
cost via the ICES costing algorithm, though it may not 
be possible to obtain only the medication cost for the 
PIP medication, as the macro currently obtains all medi-
cation costs over a designated period as opposed to the 
costs of each individual medication. Should we be unable 
to obtain PIP medication costs via the macro, we will 
identify the lowest hypothetical medication costs for each 
PIP via the prescribe smart mobile application,44 which 
provides the drug unit price of all available drugs within 
Ontario and allows for easy comparison within class, at 
WHO Defined Daily Dose for each drug.45 The drug 
cost of a daily dose will be multiplied by 90 to obtain the 
most conservative estimate of a 90-day supply to match 
the observation window. The highest and median prices 
for each PIP will also be obtained and used in sensitivity 
Figure 2 Assessment of potentially inappropriate prescription (PIP) frequency by crude costs (from hospitalisations, 
emergency department visits and medications) to determine PIP scenarios to be modelled.  
Table 1 Definitions for PIP criteria to be modelled as part 







ACE inhibitor with systolic heart 









patients with delirium or dementia 





Androgens (male sex hormones) 
in the absence of primary or 
secondary hypogonadism 
(risk of androgen toxicity; no 
proven benefit outside of the 
hypogonadism indication).
Low Low
PIP, potentially inappropriate prescription; STOPP, Screening 
Tool of Older Persons’ Prescriptions; START, Screening Tool to 
Alert doctors to Right Treatment. 
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analyses, should this approach be used, to observe the PIP 
costing method’s impact on incremental costs.
Covariates
The covariates of interest for objective 2 will be the same 
as in objective 1. Where they differ is in the assignment 
of the PIP date for ascertainment of covariate status in 
participants not experiencing a PIP. In objective 2, a 
subset of participants not experiencing a PIP will be 
selected for inclusion into the analysis based on having 
an exact, or similar, index date as a participant with a 
PIP. Once included, participants without a PIP will be 
assigned the same PIP date as the person with whom they 
share the exact or similar index date. This approach to 
participant inclusion and PIP date assignment has been 
selected since an efficient approach for participant selec-
tion and PIP date assignment that would be least likely to 
bias study results is necessary. The number of participants 
with the PIPs of interest ranges from several thousand 
to over 200 000, thus the number of unexposed partici-
pant’s needs to be reduced in size for each of the analyses, 
precluding the inclusion of all unexposed participants in 
the cohort. Additionally, the index date is the least likely 
of all available covariates at time of participant selection 
to be associated with PIP or cost and outcomes, thus 
reducing the potential of introducing bias in participant 
selection.
Statistical analyses
The incremental costs associated with having each of the 
individual PIP criterion described in table 1 versus not 
having the PIP in question will be modelled using regres-
sion analyses. Due to the typical distribution associated 
with cost data, multiple candidate models will be assessed 
to identify the model that best fits the data. This process 
will begin with the fitting of an ordinary least squares 
regression and assessment of model fit, as well as a check 
for heteroscedasticity. If there is evidence of heterosce-
dasticity, we will then proceed with the selection of a 
generalised linear model. The link function and variance 
structure to be used will be determined using the TRAN-
SREG function in SAS and modified Park’s test, respec-
tively. Should the Poisson variance structure be selected, 
the mean of the costs will be compared with the variance 
to determine whether overdispersion is present and 
whether a negative binomial model is preferred. All candi-
date models will be adjusted for the covariates described 
above. Each model’s performance will be assessed using 
the Bayesian information criterion and graphical check 
of the distribution fit comparing the distribution of the 
predicted values with the expected values.
Patient and public involvement
The research questions addressed by this protocol 
were informed by the values and preferences of 
patients with regards to reducing their medication 
burden and improving their health outcomes, though 
no patients or public were directly involved in the 
development of this protocol. Results of this study will 
be disseminated to patient groups within our research 
networks.
EthICs And dIssEMInAtIon
safety and confidentiality considerations
This study makes use of previously collected health 
administrative databases housed at ICES, accessed from 
ICES@uOttawa, and does not require any additional 
intervention or data collection at the patient level. ICES 
links deidentified population-based health information 
at the population level in a way that ensures privacy and 
confidentiality to participants. As per ICES procedures, 
cell sizes of less than five will not be reported to address 
concerns about possible breaches of confidentiality.
dissemination
Dissemination will primarily occur via publication of 
study results and presentation at national and interna-
tional conferences. Professional networks will be used 
to promote dissemination with various stakeholders, 
including health policy-makers at the provincial and 
national levels.
statement of originality
The assessment of the economic burden of PIP and PIO 
at the population level using linked health administra-
tive databases is the first of its kind in any jurisdiction to 
the best of our knowledge. This is the first study of its 
kind leveraging linked health administrative databases to 
assess the health services costs of PIP and PIO beyond the 
medication costs alone, as well as the first study that will 
be able to adjust for potential confounders beyond age 
and sex.
Anticipated limitations
Our study is subject to limitations that are common to 
studies relying on health administrative databases which 
may affect our estimates of the prevalence of PIP and 
associated costs. It cannot be confirmed that participants 
adhered to the instructions regarding the medications 
dispensed to them, or regularly took them. Adherence to 
medication can only be assessed by comparing the date 
when an original prescription was scheduled to expire 
with the dispensation date of the renewal prescription. 
It is also difficult to determine whether some of the PIP 
identified by the STOPP/START criteria are indeed 
inappropriate without clinical or diagnostic data that are 
unavailable to us.46 Some of the STOPP/START criteria 
include over-the-counter medications or medications 
that are not covered by Ontario’s public medication plan 
(ODB), and thus are not captured in the ODBD or iden-
tified as a PIP in our database. Additionally, we are unable 
to determine the cost of PIP medications from the linked 
health administrative databases due to the complexity 
and time required to identify specific prescriptions from 
a total of over half a billion prescriptions. As such, a 
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conservative approach will be used to identify medica-
tion costs as described in the outcomes section. Despite 
these limitations, we are confident our study will produce 
useful, conservative estimates of the health system costs 
associated with PIP.
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